Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00059657 · ClinicalTrials.gov registry record · Phase 3

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

A Phase 3 study of Peripheral Vascular Disease, sponsored by Tanabe Pharma Corporation.

Completed
Registry status
Phase 3
Development phase
280
Enrollment target
20
Study locations

NCT00059657 is a Phase 3 study of Peripheral Vascular Disease that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 280 participants, roughly in line with the 271-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00059657, a Phase 3 study of Peripheral Vascular Disease, has completed, sponsored by Tanabe Pharma Corporation.

COMPLETED
Registry status
Phase 3
Development phase
280 participants
Enrollment target
20
Study locations

Study Summary

Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.

Conditions Studied

Peripheral Vascular Disease

Interventions

  • DRUG Ecraprost in lipid emulsion

Study Locations (20)

Other

  • - Birmingham
  • - Bristol
  • - Dundee
  • - Hull
  • - London

California

  • - Glendale
  • - Los Angeles
  • - San Francisco

Arizona

  • - Phoenix
  • - Tucson

Florida

  • - Pensacola

Illinois

  • - Springfield

Kansas

  • - Shawnee Mission

Louisiana

  • - Kenner

Michigan

  • - Royal Oak

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2001-08
Est. Completion 2005-11
Phase Phase 3

Sponsor

Tanabe Pharma Corporation

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00059657

The ClinicalTrials.gov registry entry for NCT00059657 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 271-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target. The listed sponsor is Tanabe Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Ecraprost in lipid emulsion is the first listed.

NCT00059657 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00059657 about?

NCT00059657 is a clinical study titled "Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease". Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.

What is the current status of trial NCT00059657?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2001-08. Estimated completion is 2005-11.

What conditions does trial NCT00059657 study?

This clinical trial studies the following conditions: Peripheral Vascular Disease.

What interventions are being tested in trial NCT00059657?

The interventions under investigation include: Ecraprost in lipid emulsion (DRUG).

Who is sponsoring clinical trial NCT00059657?

This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00059657 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Peripheral Vascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Peripheral Vascular Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.